期刊
PHARMACEUTICS
卷 14, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics14040867
关键词
cancer therapy; neoantigens; immunotherapy; vaccine
资金
- Chang Gung Memorial Hospital [CIRPG3I0041-43, CIRPG3I0021-23, CIRPG3I0031-33, CIRPG2I0011-13]
- Ministry of Science and Technology of Taiwan [MOST 108-2320-B-182A-023 -MY3, MOST 109-2320-B-182A-008-MY3]
Cancer immunotherapy has become indispensable in cancer treatment, with a focus on targeting tumor-specific antigens or neoantigens. Advanced technologies have allowed for the identification and application of neoantigens in cancer vaccines. Therapeutic vaccines have shown success in activating the immune system to kill cancer cells.
Cancer immunotherapy has achieved multiple clinical benefits and has become an indispensable component of cancer treatment. Targeting tumor-specific antigens, also known as neoantigens, plays a crucial role in cancer immunotherapy. T cells of adaptive immunity that recognize neoantigens, but do not induce unwanted off-target effects, have demonstrated high efficacy and low side effects in cancer immunotherapy. Tumor neoantigens derived from accumulated genetic instability can be characterized using emerging technologies, such as high-throughput sequencing, bioinformatics, predictive algorithms, mass-spectrometry analyses, and immunogenicity validation. Neoepitopes with a higher affinity for major histocompatibility complexes can be identified and further applied to the field of cancer vaccines. Therapeutic vaccines composed of tumor lysates or cells and DNA, mRNA, or peptides of neoantigens have revoked adaptive immunity to kill cancer cells in clinical trials. Broad clinical applicability of these therapeutic cancer vaccines has emerged. In this review, we discuss recent progress in neoantigen identification and applications for cancer vaccines and the results of ongoing trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据